Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Neliprax 0.7mg tablets
0409010W0BCACAA
|
Neliprax | Pramipexole | Central Nervous System | No data available |
|
Nemdatine 10mg tablets
0411000G0BEAAAA
|
Nemdatine | Memantine hydrochloride | Central Nervous System | No data available |
|
Nemdatine 20mg tablets
0411000G0BEABAD
|
Nemdatine | Memantine hydrochloride | Central Nervous System | No data available |
|
Nemdatine tablets treatment initiation pack
0411000G0BEACAE
|
Nemdatine | Memantine hydrochloride | Central Nervous System | No data available |
|
Neo Baby cream
130201000BBKWCX
|
Proprietary compound emollients | Other emollient preparations | Skin | No data available |
|
Neo Baby Gripe mixture
0101012A0BEAAA0
|
Neo Gripe | Gripe mixtures | Gastro-Intestinal System | No data available |
|
Neo-Cortef ear/eye drops
1201010G0BBAAAA
|
Neo-Cortef (Ear/Eye) | Hydrocortisone acetate | Ear, Nose and Oropharynx | No data available |
|
Neo-Cortef ear/eye ointment
1201010G0BBABAB
|
Neo-Cortef (Ear/Eye) | Hydrocortisone acetate | Ear, Nose and Oropharynx | No data available |
|
Neo-D 800units/ml oral drops
0906040G0CBAACJ
|
Neo-D | Colecalciferol | Nutrition and Blood | No data available |
|
Neo-Naclex 2.5mg tablets
0202010B0BEABAB
|
Neo-Naclex | Bendroflumethiazide | Cardiovascular System | No data available |
|
Neo-Naclex 5mg tablets
0202010B0BEAAAC
|
Neo-Naclex | Bendroflumethiazide | Cardiovascular System | No data available |
|
Neo-Naclex-K modified-release tablets
0202080B0BCAAAB
|
Neo-Naclex-K | Bendroflumethiazide/potassium | Cardiovascular System | No data available |
|
Neocate Active powder 63g sachets blackcurrant
0913361A0BBAAAA
|
Neocate powder discontinued amino acid formula (0913361) | Powder discontinued amino acid formula (0913361) | Nutrition and Blood | No data available |
|
Neocate Active powder 63g sachets unflavoured
0913361A0BBABAA
|
Neocate powder discontinued amino acid formula (0913361) | Powder discontinued amino acid formula (0913361) | Nutrition and Blood | No data available |
|
Neocate Advance powder 100g sachets unflavoured
0913361A0BBADAC
|
Neocate powder discontinued amino acid formula (0913361) | Powder discontinued amino acid formula (0913361) | Nutrition and Blood | No data available |
|
Neocate Advance powder 50g sachets banana & vanilla
0913361A0BBAEAC
|
Neocate powder discontinued amino acid formula (0913361) | Powder discontinued amino acid formula (0913361) | Nutrition and Blood | No data available |
|
Neocate Nutra powder gluten free
090401000BBPPA0
|
Proprietary compound foods for special diets | Other food for special diet preparations | Nutrition and Blood | No data available |
|
Neoclarityn 2.5mg/5ml syrup
0304010ABBBABAB
|
Neoclarityn | Desloratadine | Respiratory System | No data available |
|
Neofordex 40mg tablets
0603020G0BHAACJ
|
Neofordex | Dexamethasone | Endocrine System | No data available |
|
Neogest 75microgram tablets
0703021P0BBAAAA
|
Neogest | Norgestrel | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Neomel 1mg/ml oral solution
0401010ADBHAACZ
|
Neomel | Melatonin | Central Nervous System | No data available |
|
NeoMercazole 20 tablets
0602020D0BBABAB
|
NeoMercazole | Carbimazole | Endocrine System | No data available |
|
NeoMercazole 5 tablets
0602020D0BBAAAA
|
NeoMercazole | Carbimazole | Endocrine System | No data available |
|
Neomycin 0.25% / Gramicidin 0.025% ointment
1310011P0AAAJAJ
|
Neomycin sulfate (Topical) | Neomycin sulfate | Skin | No data available |
|
Neomycin 0.35% / Triamcinolone 0.1% ear drops
1201010Z0AAABAB
|
Triamcinolone acetonide (Ear) | Triamcinolone acetonide | Ear, Nose and Oropharynx | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.